Intellia Therapeutics Inc (NTLA) Given Average Rating of “Hold” by Brokerages

Intellia Therapeutics Inc (NASDAQ:NTLA) has received a consensus recommendation of “Hold” from the twelve ratings firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $30.40.

Several analysts recently weighed in on the company. Barclays reissued a “buy” rating on shares of Intellia Therapeutics in a report on Sunday, November 5th. TheStreet lowered Intellia Therapeutics from a “c-” rating to a “d” rating in a report on Thursday, December 14th. BidaskClub lowered Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 15th. ValuEngine lowered Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, November 15th. Finally, Oppenheimer reissued a “hold” rating on shares of Intellia Therapeutics in a report on Monday, December 18th.

Shares of Intellia Therapeutics (NASDAQ NTLA) opened at $22.95 on Tuesday. The firm has a market capitalization of $848.92, a PE ratio of -14.71 and a beta of 3.60. Intellia Therapeutics has a fifty-two week low of $10.83 and a fifty-two week high of $33.34.

In other Intellia Therapeutics news, major shareholder Caribou Biosciences, Inc. sold 550,645 shares of Intellia Therapeutics stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $26.78, for a total value of $14,746,273.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Institutes For Biomed Novartis sold 1,523,000 shares of Intellia Therapeutics stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $18.30, for a total value of $27,870,900.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 2,521,928 shares of company stock valued at $51,883,434. 12.80% of the stock is currently owned by insiders.

A number of hedge funds have recently modified their holdings of NTLA. Schwab Charles Investment Management Inc. boosted its stake in Intellia Therapeutics by 58.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 42,674 shares of the company’s stock valued at $683,000 after acquiring an additional 15,771 shares during the period. Rhumbline Advisers acquired a new position in shares of Intellia Therapeutics during the second quarter worth approximately $275,000. Bank of New York Mellon Corp boosted its position in shares of Intellia Therapeutics by 73.0% during the second quarter. Bank of New York Mellon Corp now owns 54,802 shares of the company’s stock worth $876,000 after buying an additional 23,126 shares during the period. Wells Fargo & Company MN boosted its position in shares of Intellia Therapeutics by 176.1% during the second quarter. Wells Fargo & Company MN now owns 30,215 shares of the company’s stock worth $483,000 after buying an additional 19,270 shares during the period. Finally, Alliancebernstein L.P. boosted its position in shares of Intellia Therapeutics by 17.8% during the second quarter. Alliancebernstein L.P. now owns 30,400 shares of the company’s stock worth $486,000 after buying an additional 4,600 shares during the period. Institutional investors own 48.12% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Intellia Therapeutics Inc (NTLA) Given Average Rating of “Hold” by Brokerages” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/02/06/intellia-therapeutics-inc-ntla-given-average-rating-of-hold-by-brokerages.html.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply